We can't find the internet
Attempting to reconnect
14032.1;10 PFLS-LS
Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)
Résumé
Development of balanced dual PI3K/mTOR kinase inhibitors: A new generation of potential drugs for targeted cancer therapy (solid tumors)
Textes supplémentaires
Abstract
The proposed CTI project aims to develop PI3K/mTOR kinase inhibitors as a new generation of drugs for the treatment of solid tumors such as pancreatic cancer. The designed approach allows discovery and development of lipid-modifying enzyme inhibitors. The methodology and the products complement the existing PIQUR technology portfolio, and open a new branch of commercial opportunities. The project is expected to support current PIQUR activities by identifying a best-in-class clinical candidate, which in comparison with the competitor compounds of same mode of action, has a balanced dual PI3K/mTOR inhibition and improved pharmacological properties, providing optimal therapies, tailored to the unique needs of solid tumors.
Participants
Matthias Wymann
Kontaktperson
matthias.wymann@unibas.ch
Universität Basel Matthias Wymann Mattenstrasse 28 4058 Basel BS CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2012-05-31
- Date de fin
- 2014-10-22
- Coûts totaux approuvés
- CHF 581283.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Nicht aufteilbare / nicht zuteilbare Forschung
Disciplines de recherche
- P004 Biochemistry, Metabolism 100.0%